Related Experiment Video
Updated: May 22, 2026
11:19
Guidelines for Elective Pediatric Fiberoptic Intubation
Published on: January 17, 2011
Fluconazole use and safety in the nursery
E Castagnola1, E Jacqz-Aigrain, F Kaguelidou
1Infectious Disease Unit, Gaslini Institute, Genova, Italy.
Early Human Development
|May 29, 2012
Summary
Fluconazole is a key antifungal for neonates, but optimal dosing and long-term safety in premature infants require further study. Recent trials offer new insights into its use in neonatal intensive care units.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Infectious Diseases
Background:
- Fluconazole, a triazole antifungal, is widely used in neonatal intensive care units (NICUs).
- It is available in intravenous and oral forms, effective against common neonatal fungal pathogens.
- Despite extensive use, robust safety and efficacy data in neonates, especially premature infants, remain limited.
Purpose of the Study:
- To review recent evidence on fluconazole's use in NICU settings.
- To address uncertainties regarding fluconazole pharmacokinetics, dosing, and safety in neonates.
- To discuss ongoing debates on optimal dosing strategies and long-term safety profiles.
Main Methods:
- Review of recent randomized clinical trials and studies on fluconazole in neonates.
- Analysis of existing literature on fluconazole pharmacokinetics and safety in premature and term infants.
- Examination of current debates regarding dosing strategies and prophylactic use.
Main Results:
- Recent randomized trials have provided new data on fluconazole's effectiveness in preventing systemic fungal infections.
- Uncertainties persist regarding optimal dosing, particularly in different subgroups of preterm infants.
- Long-term safety data, especially for prophylactic use in extremely premature infants, are still under investigation.
Conclusions:
- Fluconazole remains a crucial antifungal agent in NICU settings.
- Further research is needed to establish definitive dosing guidelines and confirm long-term safety in vulnerable infant populations.
- Ongoing studies aim to resolve current debates and optimize fluconazole therapy for neonates.
Related Concept Videos
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:28Development of the Oral Microbiota
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...